ATAI LIFE SCIENCES N.V. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.84 USD | -1.60% |
|
-3.66% | +30.50% |
Presenter SpeechGregory Weaver (Executives)Hi, everyone, and welcome, and thanks for joining u...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The Company engages in developing various treatments that focuses on various mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.87
USD
Average target price
11.8
USD
Spread / Average Target
+531.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +30.50% | 313M | |
| +1.40% | 43.84B | |
| +7.06% | 41.68B | |
| +45.26% | 41.25B | |
| -11.96% | 27.04B | |
| +7.10% | 25.53B | |
| -24.38% | 18.18B | |
| -3.38% | 12.29B | |
| +27.48% | 12.29B | |
| +7.49% | 11.15B |
- Stock Market
- Equities
- ATAI Stock
- News Atai Life Sciences N.V.
- Transcript : Atai Life Sciences N.V., Q2 2022 Earnings Call, Aug 15, 2022
